Mirum Pharmaceuticals stock surged 25% and how LIVMARLI drives growth. Explore future prospects with Volixibat. Click here to ...

Mirum Pharmaceuticals, Inc. shows strong growth with a 43% revenue jump and promising pipeline assets. Click here for my ...

Mirum Pharmaceuticals’ MIRM lead product, Livmarli (maralixibat), an orally administered ileal bile acid transporter (“IBAT”) ...

Raymond James Financial Inc. bought a new stake in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM – Free Report) during ...

In the last week, the United States market has remained flat, yet it has achieved an 8.1% increase over the past year with earnings anticipated to grow by 14% annually in the coming years. In this ...

AlphaQuest LLC increased its position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM – Free Report) by 969.6% in the 4th quarter ...

Revenue: US$336.9m (up 81% from FY 2023). Net loss: US$87.9m (loss narrowed by 46% from FY 2023). US$1.85 loss per share (improved from US$4.00 loss in FY 2023). Revenue was in line with analyst ...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on March 10, 2025, the Compensation Committee of Mirum’s Board of Directors granted ...

Try Now>> See today’s best-performing stocks on TipRanks >> Read More on MIRM: Mirum Pharmaceuticals NewsMORE Related Stocks Indices Commodities Currencies Stocks ...